INDUCTION CHEMOTHERAPY WITH FOLFOXIRI PLUS CETUXIMAB AND MAINTENANCE WITH CETUXIMAB OR BEVACIZUMAB THERAPY IN UNRESECTABLE KRAS WILD-TYPE METASTATIC COLORECTAL CANCER PATIENTS

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Bevacizumab (Primary) ; Cetuximab (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
Indications Colorectal cancer
Focus Therapeutic Use
Acronyms MACBETH

15 Jun 2020 A pooled analysis of five prospective trials; results published in the European Journal of Cancer
13 Mar 2018 Results of a pooled analysis of five prospective trials ((NCT00719797, NCT02271464, NCT02295930, EudraCT2008-001062-93 and NCT02086656; n=153) assessing prognostic impact of histopathologic parameters, published in the British Journal of Cancer
11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com